This research demonstrates that radiotherapy significantly improves the effectiveness of adeno-associated virus (AAV) gene therapy by triggering epigenetic changes that boost transgene expression. Scientists developed a specialized AAV platform using an interferon-inducible promoter to ensure that therapeutic cytokines, specifically IL-12, are only produced within the irradiated tumor site. This localized approach prevents the systemic toxicity typically associated with cytokine treatments while effectively transforming "cold" tumors into "hot," immune-active environments. The combination of radiation and AAV-iIL12 stimulates a robust antitumor response driven by IFNγ and FAS-mediated cell death. Remarkably, this dual strategy generates systemic immunity capable of attacking distant metastases and overcoming common resistance mechanisms. These findings establish a safer, more potent immuno-gene therapy framework that leverages the biological synergy between radiation and viral vectors.

References:

• Marco S, Fernández M, Honorato B, et al. Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity[J]. Cancer Cell, 2026.